{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:26:02Z","timestamp":1771471562748,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Institute of Heart Diseases, Wroclaw Medical University","award":["SUBZ.A460.22.055"],"award-info":[{"award-number":["SUBZ.A460.22.055"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Heart Fail Rep"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Iron deficiency (ID) complicates heart failure (HF) at different stages of the natural history of the disease; however, this frequent comorbidity is still not comprehensively understood and investigated in terms of pathophysiology. Intravenous iron therapy with ferric carboxymaltose (FCM) should be considered to improve the quality of life, exercise capacity, and symptoms in stable HF with ID, as well as to reduce HF hospitalizations in iron-deficient patients stabilized after an episode of acute HF. The therapy with intravenous iron, however, continues to generate important clinical questions for cardiologists.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>In the current paper, we discuss the class effect concept for intravenous iron formulations beyond FCM, based on the experiences of nephrologists who administer different intravenous iron formulations in advanced chronic kidney disease complicated with ID and anemia. Furthermore, we discuss the neutral effects of oral iron therapy in patients with HF, because there are still some reasons to further explore this route of supplementation. The different definitions of ID applied in HF studies and new doubts regarding possible interactions of intravenous iron with sodium-glucose co-transporter type 2 inhibitors are also emphasized.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>The experiences of other medical specializations may provide new information on how to optimally replenish iron in patients with HF and ID.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11897-023-00611-3","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T06:01:56Z","timestamp":1688968916000},"page":"300-307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?"],"prefix":"10.1007","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5426-5432","authenticated-orcid":false,"given":"Micha\u0142","family":"Tkaczyszyn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8671-7007","authenticated-orcid":false,"given":"Marat","family":"Fudim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-7064","authenticated-orcid":false,"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"611_CR1","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/ehf2.13265","volume":"8","author":"G Loncar","year":"2021","unstructured":"Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in heart failure. ESC Heart Fail. 2021;8:2368\u201379. https:\/\/doi.org\/10.1002\/ehf2.13265.","journal-title":"ESC Heart Fail"},{"key":"611_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","volume":"7","author":"S von Haehling","year":"2019","unstructured":"von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD. Iron deficiency in heart failure: an overview. JACC Heart Fail. 2019;7:36\u201346. https:\/\/doi.org\/10.1016\/j.jchf.2018.07.015.","journal-title":"JACC Heart Fail"},{"key":"611_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/eurheartj\/ehac569","volume":"44","author":"G Savarese","year":"2023","unstructured":"\u2022\u2022 Savarese G, von Haehling S, Butler J, Cleland JGF, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Eur Heart J. 2023;44:14\u201327. https:\/\/doi.org\/10.1093\/eurheartj\/ehac569. Comprehensive review on iron deficiency in cardiovascular disease.","journal-title":"Eur Heart J"},{"key":"611_CR4","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, Burri H, Butler J, \u010celutkien\u0117 J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document Group. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"611_CR5","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ejhf.473","volume":"18","author":"EA Jankowska","year":"2016","unstructured":"Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. Eur J Heart Fail. 2016;18:786\u201395. https:\/\/doi.org\/10.1002\/ejhf.473.","journal-title":"Eur J Heart Fail"},{"key":"611_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ejhf.823","volume":"20","author":"SD Anker","year":"2018","unstructured":"Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, L\u00fcscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. Eur J Heart Fail. 2018;20:125\u201333. https:\/\/doi.org\/10.1002\/ejhf.823.","journal-title":"Eur J Heart Fail"},{"key":"611_CR7","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, Fabien V, Filippatos G, G\u00f6hring UM, Keren A, Khintibidze I, Kragten H, Martinez FA, Metra M, Milicic D, Nicolau JC, Ohlsson M, Parkhomenko A, Pascual-Figal DA, Ruschitzka F, Sim D, Skouri H, van der Meer P, Lewis BS, Comin-Colet J, von Haehling S, Cohen-Solal A, Danchin N, Doehner W, Dargie HJ, Motro M, Butler J, Friede T, Jensen KH, Pocock S, Jankowska EA, AFFIRM-AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895\u2013904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4.","journal-title":"Lancet"},{"key":"611_CR8","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, Ahmed FZ, Al-Mohammad A, Cowburn PJ, Foley PWX, Graham FJ, Japp AG, Lane RE, Lang NN, Ludman AJ, Macdougall IC, Pellicori P, Ray R, Robertson M, Seed A, Ford I, IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400:2199\u2013209. https:\/\/doi.org\/10.1016\/S0140-6736(22)02083-9.","journal-title":"Lancet"},{"key":"611_CR9","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Anker SD, Shahzeb Khan M, Butler J, von Haehling S, Jankowska EA, Ponikowski P, Friede T. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis. Eur J Heart Fail. 2023 (in press). https:\/\/doi.org\/10.1002\/ejhf.2860. Recent meta-analysis combining individual patient data from FAIR-HF, CONFIRM-HF, and AFFIRM-AHF trials with IRONMAN results; it has been demonstrated that in a broad range of HFrEF patients with ID the therapy with intravenous iron reduced the composite of HF hospitalization or cardiovascular death.","DOI":"10.1002\/ejhf.2860"},{"key":"611_CR10","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.jacc.2007.07.029","volume":"50","author":"JE Toblli","year":"2007","unstructured":"Toblli JE, Lombra\u00f1a A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50:1657\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2007.07.029.","journal-title":"J Am Coll Cardiol"},{"key":"611_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","volume":"51","author":"DO Okonko","year":"2008","unstructured":"Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol. 2008;51:103\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.036.","journal-title":"J Am Coll Cardiol"},{"key":"611_CR12","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1136\/heartjnl-2022-321304","volume":"108","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JG, Petrie MC, Ahmed FZ, Foley PW, Kalra PA, Lang NN, Lane RE, Macdougall IC, Pellicori P, Pope MTB, Robertson M, Squire IB, Thomson EA, Ford I. Rationale and design of a randomised trial of intravenous iron in patients with heart failure. Heart. 2022;108:1979\u201385. https:\/\/doi.org\/10.1136\/heartjnl-2022-321304.","journal-title":"Heart"},{"key":"611_CR13","doi-asserted-by":"publisher","unstructured":"McEwan P, Harrison C, Binnie R, Lewis RD, Cohen-Solal A, Lund LH, Ohlsson M, von Haehling S, Comin-Colet J, Pascual-Figal DA, W\u00e4chter S, Dorigotti F, de Arellano AR, Ponikowski P, Jankowska EA. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation. Eur J Heart Fail. 2023 (in press). https:\/\/doi.org\/10.1002\/ejhf.2788.","DOI":"10.1002\/ejhf.2788"},{"key":"611_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13696998.2022.2155375","volume":"26","author":"P McEwan","year":"2023","unstructured":"McEwan P, Ponikowski P, Shiri T, Rosano GMC, Coats AJS, Dorigotti F, Ramirez de Arellano A, Jankowska EA. Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study. J Med Econ. 2023;26:51\u201360. https:\/\/doi.org\/10.1080\/13696998.2022.2155375.","journal-title":"J Med Econ"},{"key":"611_CR15","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/ejhf.2270","volume":"23","author":"P McEwan","year":"2021","unstructured":"McEwan P, Ponikowski P, Davis JA, Rosano G, Coats AJS, Dorigotti F, O\u2019Sullivan D, Ramirez de Arellano A, Jankowska EA. Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF. Eur J Heart Fail. 2021;23:1687\u201397. https:\/\/doi.org\/10.1002\/ejhf.2270.","journal-title":"Eur J Heart Fail"},{"key":"611_CR16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/ehf2.13221","volume":"8","author":"M Wideqvist","year":"2021","unstructured":"Wideqvist M, Cui X, Magnusson C, Schaufelberger M, Fu M. Hospital readmissions of patients with heart failure from real world: timing and associated risk factors. ESC Heart Fail. 2021;8:1388\u201397. https:\/\/doi.org\/10.1002\/ehf2.13221.","journal-title":"ESC Heart Fail"},{"key":"611_CR17","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S2352-3026(19)30264-9","volume":"7","author":"M Auerbach","year":"2020","unstructured":"Auerbach M, Gafter-Gvili A, Macdougall IC. Intravenous iron: a framework for changing the management of iron deficiency. Lancet Haematol. 2020;7:e342\u201350. https:\/\/doi.org\/10.1016\/S2352-3026(19)30264-9.","journal-title":"Lancet Haematol"},{"key":"611_CR18","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjh.17202","volume":"193","author":"D Rund","year":"2021","unstructured":"Rund D. Intravenous iron: do we adequately understand the short- and long-term risks in clinical practice? Br J Haematol. 2021;193:466\u201380. https:\/\/doi.org\/10.1111\/bjh.17202.","journal-title":"Br J Haematol"},{"key":"611_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","volume":"31","author":"EK Batchelor","year":"2020","unstructured":"Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment. J Am Soc Nephrol. 2020;31:456\u201368. https:\/\/doi.org\/10.1681\/ASN.2019020213.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 1","key":"611_CR20","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1111\/hdi.12560","volume":"21","author":"M Auerbach","year":"2017","unstructured":"Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83-92. https:\/\/doi.org\/10.1111\/hdi.12560.","journal-title":"Hemodial Int"},{"key":"611_CR21","doi-asserted-by":"publisher","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","volume":"75","author":"B Schaefer","year":"2020","unstructured":"Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H. Intravenous iron supplementation therapy. Mol Aspects Med. 2020;75:100862. https:\/\/doi.org\/10.1016\/j.mam.2020.100862.","journal-title":"Mol Aspects Med"},{"key":"611_CR22","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","volume":"26","author":"PE Pergola","year":"2019","unstructured":"Pergola PE, Fishbane S, Ganz T. Novel oral iron therapies for iron deficiency anemia in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26:272\u201391. https:\/\/doi.org\/10.1053\/j.ackd.2019.05.002.","journal-title":"Adv Chronic Kidney Dis"},{"key":"611_CR23","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1001\/jama.2017.5427","volume":"317","author":"GD Lewis","year":"2017","unstructured":"Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, Tang WHW, LaRue SJ, Redfield MM, Semigran MJ, Givertz MM, Van Buren P, Whellan D, Anstrom KJ, Shah MR, Desvigne-Nickens P, Butler J, Braunwald E, NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317:1958\u201366. https:\/\/doi.org\/10.1001\/jama.2017.5427.","journal-title":"JAMA"},{"key":"611_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/ejhf.236","volume":"17","author":"T McDonagh","year":"2015","unstructured":"McDonagh T, Macdougall IC. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? Eur J Heart Fail. 2015;17:248\u201362. https:\/\/doi.org\/10.1002\/ejhf.236.","journal-title":"Eur J Heart Fail"},{"key":"611_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3390\/jcm11010125","volume":"11","author":"RIS Alnuwaysir","year":"2021","unstructured":"Alnuwaysir RIS, Hoes MF, van Veldhuisen DJ, van der Meer P, Grote BN. Iron deficiency in heart failure: mechanisms and pathophysiology. J Clin Med. 2021;11:125. https:\/\/doi.org\/10.3390\/jcm11010125.","journal-title":"J Clin Med"},{"key":"611_CR26","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/MCO.0b013e32830a4c6e","volume":"11","author":"A Sandek","year":"2008","unstructured":"Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11:632\u20139. https:\/\/doi.org\/10.1097\/MCO.0b013e32830a4c6e.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"611_CR27","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1016\/j.clnu.2021.07.027","volume":"40","author":"A Fern\u00e1ndez-Pombo","year":"2021","unstructured":"Fern\u00e1ndez-Pombo A, Rodr\u00edguez-Carnero G, Castro AI, Cant\u00f3n-Blanco A, Seoane LM, Casanueva FF, Crujeiras AB, Mart\u00ednez-Olmos MA. Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure. Clin Nutr. 2021;40:5141\u201355. https:\/\/doi.org\/10.1016\/j.clnu.2021.07.027.","journal-title":"Clin Nutr"},{"key":"611_CR28","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacc.2009.08.012","volume":"54","author":"V Soukoulis","year":"2009","unstructured":"Soukoulis V, Dihu JB, Sole M, Anker SD, Cleland J, Fonarow GC, Metra M, Pasini E, Strzelczyk T, Taegtmeyer H, Gheorghiade M. Micronutrient deficiencies an unmet need in heart failure. J Am Coll Cardiol. 2009;54:1660\u201373. https:\/\/doi.org\/10.1016\/j.jacc.2009.08.012.","journal-title":"J Am Coll Cardiol"},{"key":"611_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/joim.13456","volume":"291","author":"N Bomer","year":"2022","unstructured":"Bomer N, Pavez-Giani MG, Grote Beverborg N, Cleland JGF, van Veldhuisen DJ, van der Meer P. Micronutrient deficiencies in heart failure: mitochondrial dysfunction as a common pathophysiological mechanism? J Intern Med. 2022;291:713\u201331. https:\/\/doi.org\/10.1111\/joim.13456.","journal-title":"J Intern Med"},{"key":"611_CR30","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.3390\/ijms20225627","volume":"20","author":"N Cvetinovic","year":"2019","unstructured":"Cvetinovic N, Loncar G, Isakovic AM, von Haehling S, Doehner W, Lainscak M, Farkas J. Micronutrient depletion in heart failure: common, clinically relevant and treatable. Int J Mol Sci. 2019;20:5627. https:\/\/doi.org\/10.3390\/ijms20225627.","journal-title":"Int J Mol Sci"},{"key":"611_CR31","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1182\/blood-2002-10-3235","volume":"101","author":"E Nemeth","year":"2003","unstructured":"Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101:2461\u20133. https:\/\/doi.org\/10.1182\/blood-2002-10-3235.","journal-title":"Blood"},{"key":"611_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ajh.23110","volume":"87","author":"CC Sun","year":"2012","unstructured":"Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392\u2013400. https:\/\/doi.org\/10.1002\/ajh.23110.","journal-title":"Am J Hematol"},{"key":"611_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/eurheartj\/ehs377","volume":"34","author":"EA Jankowska","year":"2013","unstructured":"Jankowska EA, Malyszko J, Ardehali H, Koc-Zorawska E, Banasiak W, von Haehling S, Macdougall IC, Weiss G, McMurray JJ, Anker SD, Gheorghiade M, Ponikowski P. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34:827\u201334. https:\/\/doi.org\/10.1093\/eurheartj\/ehs377.","journal-title":"Eur Heart J"},{"key":"611_CR34","doi-asserted-by":"publisher","first-page":"CD007857","DOI":"10.1002\/14651858.CD007857.pub3","volume":"2","author":"EL O'Lone","year":"2019","unstructured":"O\u2019Lone EL, Hodson EM, Nistor I, Bolignano D, Webster AC, Craig JC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2019;2:CD007857. https:\/\/doi.org\/10.1002\/14651858.CD007857.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"611_CR35","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ejhf.2092","volume":"23","author":"A Karavidas","year":"2021","unstructured":"Karavidas A, Troganis E, Lazaros G, Balta D, Karavidas IN, Polyzogopoulou E, Parissis J, Farmakis D. Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study. Eur J Heart Fail. 2021;23:593\u20137. https:\/\/doi.org\/10.1002\/ejhf.2092.","journal-title":"Eur J Heart Fail"},{"key":"611_CR36","doi-asserted-by":"publisher","unstructured":"Martens P, Yu S, Larive B, Borlaug BA, Erzurum SC, Farha S, Finet JE, Grunig G, Hemnes AR, Hill NS, Horn EM, Jacob M, Kwon DH, Park MM, Rischard FP, Rosenzweig EB, Wilcox JD, Tang WHW, PVDOMICS Study Group. Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications. Eur Heart J. 2023:ehad149 (in press). https:\/\/doi.org\/10.1093\/eurheartj\/ehad149.","DOI":"10.1093\/eurheartj\/ehad149"},{"key":"611_CR37","doi-asserted-by":"publisher","unstructured":"Filippatos G, Ponikowski P, Farmakis D, Anker SD, Butler J, Fabien V, Kirwan BA, Macdougall IC, Metra M, Rosano G, Ruschitzka F, van der Meer P, Waechter S, Jankowska EA, AFFIRM-AHF (randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality in iron-deficient subjects admitted for acute heart failure) investigators. Association between hemoglobin levels and efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency: an AFFIRM-AHF subgroup analysis. Circulation. 2023 (in press). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060757.","DOI":"10.1161\/CIRCULATIONAHA.122.060757"},{"key":"611_CR38","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1161\/CIRCULATIONAHA.118.038516","volume":"139","author":"G Charles-Edwards","year":"2019","unstructured":"\u2022\u2022 Charles-Edwards G, Amaral N, Sleigh A, Ayis S, Catibog N, McDonagh T, Monaghan M, Amin-Youssef G, Kemp GJ, Shah AM, Okonko DO. Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency. Circulation. 2019;139:2386\u201398. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038516. An elegant mechanistic study demonstrating, that in patients with chronic HF and iron deficiency iron isomaltoside improved indices of skeletal muscle energetics.","journal-title":"Circulation"},{"key":"611_CR39","doi-asserted-by":"publisher","first-page":"17000","DOI":"10.3390\/ijerph192417000","volume":"19","author":"M Tkaczyszyn","year":"2022","unstructured":"Tkaczyszyn M, G\u00f3rniak KM, Lis WH, Ponikowski P, Jankowska EA. Iron deficiency and deranged myocardial energetics in heart failure. Int J Environ Res Public Health. 2022;19:17000. https:\/\/doi.org\/10.3390\/ijerph192417000.","journal-title":"Int J Environ Res Public Health"},{"key":"611_CR40","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10741-018-9738-4","volume":"24","author":"KA Kobak","year":"2019","unstructured":"Kobak KA, Radwa\u0144ska M, Dzi\u0119ga\u0142a M, Kasztura M, Josiak K, Banasiak W, Ponikowski P, Jankowska EA. Structural and functional abnormalities in iron-depleted heart. Heart Fail Rev. 2019;24:269\u201377. https:\/\/doi.org\/10.1007\/s10741-018-9738-4.","journal-title":"Heart Fail Rev"},{"key":"611_CR41","doi-asserted-by":"publisher","unstructured":"Metra M, Jankowska EA, Pagnesi M, Anker SD, Butler J, Dorigotti F, Fabien V, Filippatos G, Kirwan BA, Macdougall IC, Rosano G, Ruschitzka F, Tomasoni D, van der Meer P, Ponikowski P, AFFIRM-AHF Investigators. Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial. Eur J Heart Fail. 2022;24:1928\u201339. https:\/\/doi.org\/10.1002\/ejhf.2630.","DOI":"10.1002\/ejhf.2630"},{"key":"611_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cardfail.2022.11.006","volume":"29","author":"M Packer","year":"2023","unstructured":"Packer M. Increases in fibroblast growth factor 23 during treatment with ferric carboxymaltose: potential adverse effects on the heart and kidneys. J Card Fail. 2023;29:229\u201331. https:\/\/doi.org\/10.1016\/j.cardfail.2022.11.006.","journal-title":"J Card Fail"},{"key":"611_CR43","doi-asserted-by":"publisher","unstructured":"Gertler C, Jauert N, Freyhardt P, Valentova M, Aland SC, Walter-Rittel TC, Unterberg-Buchwald C, Placzek M, Ding-Reinelt V, Bekfani T, Doehner W, Hasenfu\u00df G, Hamm B, Sandek A. Magnetic resonance imaging of organ iron before and after correction of iron deficiency in patients with heart failure. ESC Heart Fail. 2023 (in press). https:\/\/doi.org\/10.1002\/ehf2.14329.","DOI":"10.1002\/ehf2.14329"},{"key":"611_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/ejhf.1434","volume":"21","author":"K Ghafourian","year":"2019","unstructured":"Ghafourian K, Chang HC, Ardehali H. Intravenous iron therapy in heart failure: a different perspective. Eur J Heart Fail. 2019;21:703\u201314. https:\/\/doi.org\/10.1002\/ejhf.1434.","journal-title":"Eur J Heart Fail"},{"key":"611_CR45","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/ehf2.12477","volume":"6","author":"J Biegus","year":"2019","unstructured":"Biegus J, Demissei B, Postmus D, Cotter G, Davison BA, Felker GM, Filippatos G, Gimpelewicz C, Greenberg B, Metra M, Severin T, Teerlink JR, Voors AA, Ponikowski P. Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. ESC Heart Fail. 2019;6:1188\u201398. https:\/\/doi.org\/10.1002\/ehf2.12477.","journal-title":"ESC Heart Fail"},{"key":"611_CR46","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/ejhf.644","volume":"18","author":"J Biegus","year":"2016","unstructured":"Biegus J, Zymli\u0144ski R, Sokolski M, Siwo\u0142owski P, Gajewski P, Nawrocka-Millward S, Poniewierka E, Jankowska EA, Banasiak W, Ponikowski P. Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure. Eur J Heart Fail. 2016;18:1518\u201321. https:\/\/doi.org\/10.1002\/ejhf.644.","journal-title":"Eur J Heart Fail"},{"key":"611_CR47","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J. Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis. Eur J Heart Fail. 2017;19:522-30. https:\/\/doi.org\/10.1002\/ejhf.640.","DOI":"10.1002\/ejhf.640"},{"key":"611_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5603\/KP.a2019.0014","volume":"77","author":"J Biegus","year":"2019","unstructured":"Biegus J, Zymli\u0144ski R, Sokolski M, Jankowska EA, Banasiak W, Ponikowski P. Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome. Kardiol Pol. 2019;77:347\u201354. https:\/\/doi.org\/10.5603\/KP.a2019.0014.","journal-title":"Kardiol Pol"},{"key":"611_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","volume":"11","author":"M Packer","year":"2023","unstructured":"Packer M. Potential interactions when prescribing SGLT2 inhibitors and intravenous iron in combination in heart failure. JACC Heart Fail. 2023;11:106\u201314. https:\/\/doi.org\/10.1016\/j.jchf.2022.10.004.","journal-title":"JACC Heart Fail"},{"key":"611_CR50","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cardfail.2022.12.007","volume":"29","author":"M Packer","year":"2023","unstructured":"Packer M, Cleland JGF. Combining iron supplements with SGLT2 inhibitor-stimulated erythropoiesis in heart failure: should we be worried about thromboembolic events? J Card Fail. 2023;29:403\u20136. https:\/\/doi.org\/10.1016\/j.cardfail.2022.12.007.","journal-title":"J Card Fail"}],"container-title":["Current Heart Failure Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11897-023-00611-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11897-023-00611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T07:23:52Z","timestamp":1691738632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11897-023-00611-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1007\/s11897-023-00611-3","relation":{},"ISSN":["1546-9530","1546-9549"],"issn-type":[{"value":"1546-9530","type":"print"},{"value":"1546-9549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"assertion":[{"value":"7 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Wroclaw Medical University received an unrestricted grant from Vifor Pharma. M. T. reports personal fees from V-Wave Ltd., Eidos Therapeutics, Cytokinetics, Impulse Dynamics, Alnylam Pharmaceuticals, and Takeda, outside the submitted work. M. F. reports consulting fees from Pharmacosmos.\u00a0P. P. reports grants, personal fees and other from Vifor Pharma; personal fees and other from Bayer, Novartis, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, BMS; outside the submitted work. J. B. reports personal fees from Bayer, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}